157341-41-8

Basic information

• Product Name: DMP 777
• Synonyms: DMP 777;(2S)-N-[(1R)-1-(1,3-Benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-[(4-methyl-1-piperazinyl)carbonyl]phenoxy]-4-oxo-1-azetidinecarboxamide;L 694458;1-AzetidinecarboxaMide,N-[(1R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-[(4-Methyl-1-piperazinyl)carbonyl]phenoxy]-4-oxo-,(2S)-;(S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-Methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxaMide;(S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)phe;(S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)
• CAS NO: 157341-41-8
• Molecular Formula: C₃₁H₄₀N₄O₆
• Molecular Weight: 564.6725
• Mol File: 157341-41-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.227
• Refractive Index: 1.581
• PKA: pKa 7.04(H2O tunde?ned Iunde?ned) (Uncertain)
• CAS DataBase Reference: DMP 777(CAS DataBase Reference)
• NIST Chemistry Reference: DMP 777(157341-41-8)
• EPA Substance Registry System: DMP 777(157341-41-8)

Safety Data

• Hazardous Substances Data: 157341-41-8(Hazardous Substances Data)

Usage

General Description

DMP 777 (developed by DuPont Merck Pharmaceuticals) is a chemical compound primarily known for its potential therapeutic role as a leukocyte elastase inhibitor. It has been largely studied for its effects on the regulation of immune responses, particularly in conditions like emphysema, cystic fibrosis, and adult respiratory distress syndrome. Research has also explored its potential role in the treatment of Alzheimer's disease. DMP 777's capability to modulate immune responses makes it noteworthy within medical and scientific research. However, the full extent of its implications in therapeutic treatment is still under investigation.

InChI:InChI=1/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1

Upstream product

• 197508-43-3 (R)-N-[1-(1,3-Benzodioxol-5-yl)butylidene]-α-methylbenzene-methanamine 
• 99-96-7 4-hydroxy-benzoic acid 
• 85858-94-2 1-(4-hydroxybenzoyl)-4-methyl-piperazine 
• 120-57-0 piperonal 
• 179930-11-1 (R)-E-β-((1, 3-benzodioxol-5-ylmethylene)amino)benzene-ethanol 
• 178946-02-6 3.3-Diethyl-4S-(4'-carboxyphenoxy)-2-azetidinone 
• 181481-61-8 (S)-α-propylpiperonyl alcohol 
• 181481-62-9 1-(2H-benzo[3,4-d]1,3-dioxolan-5-yl)-(1R)-butylamine 
• 178946-03-7 (R,S)-2-[4-(benzyloxycarbonyl)phenoxy]-3,3-diethylazetidin-4-one 
• 181481-64-1 (R)-α-Propylpiperonylazide 
• 142935-44-2 4-Propionyloxy-3,3-diethylazetidin-2-one 
• 94-18-8 Benzyl 4-hydroxybenzoate 
• 63740-97-6 1-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)butan-1-one 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 6890-31-9 1-(1,3-benzodioxol-5-yl)butan-1-ol 
• 85858-94-2 1-(4-hydroxybenzoyl)-4-methyl-piperazine 

Relevant articles and documents

An efficient large-scale process for the human leukocyte elastase inhibitor, DMP 777

This report describes a new convergent, selective, and economical synthesis of DMP 777, ending with the coupling of the chiral β-lactam half of the molecule (1) to the chiral amine as the isocyanate (2). Other steps involve the coupling of the β-lactam 3 to the phenolic moiety under phase-transfer conditions, followed by resolution of the resulting piperazine derivative using a chiral acid, and recycling of the undesired enantiomer also under phase-transfer conditions. The chiral amine 4 was produced efficiently starting from (R)-α-methylbenzylamine and the corresponding butyrophenone.